Table 3.
Hematologic responses of the study population based on hATG dose
| Variable | Total patients (n = 93), n(%) | Low-dose ATG (n = 62), n(%) | Standard-dose ATG (n = 31), n(%) | P value |
|---|---|---|---|---|
| Overall response ( PR + CR) | ||||
| At 3 months | 46/93 (49.5) | 31/62 (50) | 15/31 (48.4) | 0.883 |
| At 6 months | 57/86 (66.3) | 37/58 (63.8) | 20/28 (71.4) | 0.483 |
| At 12 months | 58/80 (72.5) | 39/56 (69.6) | 19/24 (79.2) | 0.382 |
| Response at 3 months | ||||
| CR | 5/93 (5.4) | 4/62 (6.5) | 1/31 (3.2) | 0.809 |
| PR | 41/93 (44.1) | 27/62 (43.5) | 14/31 (45.2) | |
| NR | 47/93 (50.5) | 31/62 (50.0) | 16/31 (51.6) | |
| Response at 6 months | ||||
| CR | 12/86 (14.0) | 8/58 (13.8) | 4/28 (14.3) | 0.813 |
| PR | 45/86 (52.3) | 29/58 (50.0) | 16/28 (57.1) | |
| NR | 29/86 (33.7) | 21/58 (36.2) | 8/28 (28.6) | |
| Response at 12 months | ||||
| CR | 16/80 (20.0) | 10/56 (17.9) | 6/24 (25.0) | 0.614 |
| PR | 42/80 (52.5) | 29/56 (51.8) | 13/24 (54.2) | |
| NR | 22/80 (27.5) | 17/56 (30.3) | 5/24 (20.8) | |
| Best response | ||||
| CR | 44/93 (47.3) | 28/62 (45.2) | 16/31 (51.6) | 0.813 |
| PR | 28/93 (30.1) | 19/62 (30.6) | 9/31 (29.0) | |
| NR | 21/93 (22.6) | 15/62 (24.2) | 6/31 (19.4) | |
| CR after 12 months | 23/93 (24.7) | 15/62 (24.2) | 8/31 (25.8) | 0.865 |
| Time to best response (months), median(IQR) | 10 (3–18) | 12 (3–18) | 6 (3–18) | 0.635 |
| Relapse on IST | 11 (11.8) | 7 (11.3) | 4 (12.9) | 1.000 |
| Time to relapse (months), median (IQR) | 44 (20–94.5) | 51.56 (24.75–88.75) | 35.0 (10–98) | 0.330 |
| Clonal evolution | 2 (2.2) | 0 (0) | 2 (6.5) | 0.109 |